Trial investigator Emma Guttman, MD, PhD, chair of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai, here explains why targeting the OX40-OX40 ligand pathway is so exciting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback